The estimated Net Worth of Richard H Scheller is at least $13.6 Milion dollars as of 22 August 2024. Richard Scheller owns over 44,250 units of BridgeBio Pharma Inc stock worth over $979,650 and over the last 10 years he sold BBIO stock worth over $11,402,310. In addition, he makes $1,199,990 as Chairman of Research and Development i Director at BridgeBio Pharma Inc.
Richard has made over 18 trades of the BridgeBio Pharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 44,250 units of BBIO stock worth $228,330 on 22 August 2024.
The largest trade he's ever made was selling 66,241 units of BridgeBio Pharma Inc stock on 2 July 2021 worth over $1,867,996. On average, Richard trades about 7,795 units every 64 days since 2015. As of 22 August 2024 he still owns at least 35,000 units of BridgeBio Pharma Inc stock.
You can see the complete history of Richard Scheller stock trades at the bottom of the page.
Dr. Richard Henry Scheller Ph.D. serves as Chairman of Research and Development, Director of the Company. Dr. Scheller served as the Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, from 2015 to 2019. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors of Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, ORIC Pharmaceuticals, Inc., a biopharmaceutical company, Affinita Biotech, Inc., a preclinical stage biotech company and Alector, Inc. (Nasdaq: ALEC), a clinical-stage biopharmaceutical company. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology. Dr. Scheller’s qualifications to serve on our Board of Directors include his scientific background and his senior management experience in the pharmaceutical industry.
As the Chairman of Research and Development i Director of BridgeBio Pharma Inc, the total compensation of Richard Scheller at BridgeBio Pharma Inc is $1,199,990. There are 9 executives at BridgeBio Pharma Inc getting paid more, with Neil Kumar having the highest compensation of $26,334,100.
Richard Scheller is 67, he's been the Chairman of Research and Development i Director of BridgeBio Pharma Inc since 2019. There are 4 older and 18 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Richard's mailing address filed with the SEC is C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo oraz Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: